GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOUR DISEASE

This adverse event was reported 111 times

These drugs are most commonly taken by patients reporting GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOUR DISEASE:

# Drug Count
0 OCTREOTIDE ACETATE 75
1 LUTETIUM LU 177 DOTATATE 27
2 EVEROLIMUS 19
3 ONDANSETRON 8
4 ONDANSETRON HYDROCHLORIDE 8
5 CAPECITABINE 7
6 EVEROLIMUS TABLETS 7
7 LOSARTAN 7
8 TEMOZOLOMIDE 7
9 AMLODIPINE 5
See all common drugs associated with GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOUR DISEASE

GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOUR DISEASE is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 LUTETIUM LU 177 DOTATATE 27 0.0046
1 SODIUM GLYCEROPHOSPHATE 1 0.0027
2 OCTREOTIDE ACETATE 75 0.0024
3 GRANISETRON HYDROCHLORIDE 5 0.0005
4 GRANISETRON 5 0.0005
5 EVEROLIMUS TABLETS 7 0.0004
6 EVEROLIMUS 19 0.0004
7 NITROFURANTOIN MONOHYDRATE/MACROCRYSTALLINE 2 0.0003
8 TEMOZOLOMIDE 7 0.0003
9 PRAMIPEXOLE DIHYDROCHLORIDE 1 0.0002
See all drugs enriched for association with GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOUR DISEASE

GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOUR DISEASE is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Somatostatin Analog [EPC] 5 0.0007
1 Nitrofuran Antibacterial [EPC] 2 0.0001
2 Glinide [EPC] 1 0.0001
3 Antifibrinolytic Agent [EPC] 1 0.0001
4 Bile Acid Sequestrant [EPC] 1 0.0001
5 Provitamin D2 Compound [EPC] 2 0.0001
6 Serotonin-3 Receptor Antagonist [EPC] 9 0.0001
7 Vitamin D3 Analog [EPC] 1 0.0000
8 Topoisomerase Inhibitor [EPC] 3 0.0000
9 Angiotensin Converting Enzyme Inhibitor [EPC] 5 0.0000
See all drug classes enriched for association with GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOUR DISEASE